Topics

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

23:09 EDT 1 May 2019 | Reuters

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

Original Article: AstraZeneca ties up with France's Transgene to develop viral immunotherapies

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca ties up with France's Transgene to develop viral immunotherapies"

Quick Search

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...